92644-77-4Relevant academic research and scientific papers
KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 0250, (2014/10/18)
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDMIA, and methods of increasing gamma globin gene expression in a human or animal subject are also provided for the treatment diseases such as sickle cell disease.
THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
-
, (2012/08/08)
The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.
The first synthesis of nitro-substituted cyclopropanes and spiropentanes via oxidation of the corresponding amino derivatives
Volkova, Yuliya A.,Ivanova, Olga A.,Budynina, Ekaterina M.,Revunov, Eugene V.,Averina, Elena B.
experimental part, p. 2793 - 2796 (2009/09/28)
A novel approach to nitro-substituted cyclopropanes and spiropentanes via oxidation of the corresponding amines with dimethyldioxirane is reported. The method is used successfully for the preparation of a series of nitrocyclopropanes as well as for the first synthesis of 1,4-dinitrospiro[2.2]pentane.
